Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1268110


Migraine - Pipeline Assessment and Market Forecasts to 2016


Description: Migraine - Pipeline Assessment and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, “Migraine - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global migraine market. The report identifies the key trends shaping and driving the global migraine market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global migraine sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Our team of industry experts.

Scope

The report provides information on the key driver and challenges of the global migraine market. Its scope includes:
- Annualized global migraine market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include 5-HT1D agonist, 5-HT1 agonist, AMPA/kainate receptor antagonist, Neuro transmitter system receptor, bacterial Neurotoxin (muscle relaxant), 5-HT targetor, calcitonin gene related peptide (CGRP) targetors, GABA transaminase inhibitors, nitric oxide inhibitors, prostaglandin synthesis inhibitor, opioid receptor agonist, antiemetic and gastroprokinetic agents, anti-inflammatory and immunosuppressant, and cyclooxygenase-2 (COX-2) inhibitors.
- Analysis of the current and future market competition in the global migraine market. Key market players covered are GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Inc., Pozen, Inc., Eisai Co., Ltd., Johnson & Johnson, Inc., NuPathe Inc., and Abbott Laboratories.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with migraine therapeutics.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global migraine market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global migraine market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global migraine market landscape? - Identify, understand and capitalize.


Contents: 1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Migraine Market: Market Characterization
2.1 Market Overview
2.2 Overview on Accessibility of Various Migraine Treatments in the Market
2.3 Migraine Market Size
2.4 Migraine Market Forecast and CAGR
2.5 Drivers and Barriers for the Migraine Market
2.5.1 Drivers for the Migraine Market
2.5.2 Barriers for the Migraine Market
2.6 Opportunity and Unmet Need
2.7 Key Takeaway
3 Migraine Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in Migraine Market
3.3.1 ZOMIG (ZOMIG, ZOMIG-ZMT)
3.4 Maxalt
3.4.2 Frova
3.4.3 Relpax
3.4.4 Axert/Almogran
3.4.5 Amerge
3.5 Key Takeaway
4 Migraine Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Migraine Therapeutics - Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 BOTOX
4.4.2 Tezampanel
4.4.3 Telcagepant
4.5 Migraine Therapeutic Market - Clinical Pipeline by Mechanism of Action
4.6 Migraine Pipeline - Pipeline by Clinical Phases of Development
4.6.1 Migraine Therapeutics - Phase III Clinical Pipeline
4.6.2 Migraine Therapeutics - Phase II Clinical Pipeline
4.6.3 Migraine Therapeutics - Phase I Clinical Pipeline
4.6.4 Migraine Therapeutics - Preclinical Pipeline
4.6.5 Migraine Therapeutics - Discovery Pipeline
4.7 Discontinued/ Suspended Drugs for Migraine
4.8 Key Takeaway
5 Migraine Market: Implications for Future Market Competition
6 Migraine Market: Future Players in the Migraine Market
6.1 Introduction
6.2 GlaxoSmithKline
6.2.1 Company Overview
6.2.2 Business Description
6.2.3 Migraine Pipeline Overview
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Business Description
6.3.3 Migraine Pipeline Overview
6.4 Merck & Co Inc
6.4.1 Company Overview
6.4.2 Business Description
6.4.3 Migraine Pipeline Overview
6.5 POZEN Inc.
6.5.1 Overview
6.5.2 Business Description
6.5.3 Migraine Pipeline Overview
7 Migraine Market: Appendix
7.1 Definitions
7.2 Scope of Pipeline Research
7.3 Abbreviations
7.4 Research Methodology
7.4.1 Coverage
7.4.2 Secondary Research
7.4.3 Forecasting
7.4.4 Primary Research
7.4.5 Expert Panels
7.5 Contact Us
7.6 Disclaimer
7.7 Sources


Summary: “Migraine - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global migraine market. The report identifies the key trends shaping and driving the global migraine market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioningos of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global migraine sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.

The Migraine Market Has Declined Since 2009 and This Decline is Forecast to Continue until 2016

GlobalData estimated the global migraine market to be worth $3.8 billion in 2009. It is forecast to decrease at a Compound Annual Growth Rate (CAGR) of -3% over the next seven years to reach $3.1 billion by 2016. This decrease in the growth rate can be primarily attributed to the increased competition among the existing products, the patent expiries of standard triptans, the availability of prophylactic drugs, the accessibility of cheaper pain relievers, a weak pipeline with limited drugs and high levels of patient satisfaction with generic and me-too drugs. The migraine market finished its mature phase in 2009 and has since entered into a declining phase in terms of revenue. This decline is expected to continue to 2016. Until 2008, GlaxoSmithKline led the migraine market with its blockbuster drug Imitrex. On August 6, 2008, Imitrex lost its patent exclusivity, which decreased its sales from $1 billion to less than $200m in 2009.

Migraine Competitive Landscape Remains Static

The authors have found that GlaxoSmithKline plc. (GSK), Eli Lilly and Company, Merck & Co., Inc., Pozen, Inc., Eisai Co., Ltd., Johnson & Johnson, NuPathe Inc. and Abbott Laboratories are the leading competitors in the global migraine market. Together, these companies accounted for more than 40% of the global migraine market in 2009. The rest of the market was held by generic versions and prophylactic migraine drugs that include beta blockers, calcium channel blockers, anti-depressants and anticonvulsants. After the expiry of the patent on GSK’s Imitrex in mid 2008, the migraine market declined sharply. Until the end of 2007, Imitrex was the market leader, generating revenues worth more than $1.5 billion. GSK had three approved drugs in the migraine market until the end of 2008. Due to the expiry of these three drugs’ patents, GSK’s revenues in the migraine market will decline until its pipeline drugs are launched.


Companies Mentioned GlaxoSmithKline Eli Lilly and Company Merck & Co Inc POZEN Inc


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/1268110

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 13/02/2012 00:44:16
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Migraine - Pipeline Assessment and Market Forecasts to 2016
Web Address:
http://www.researchandmarkets.com/reports/1268110
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €1,529.00
Electronic (PDF) - Site License €3,057.00
Electronic (PDF) - Enterprisewide €4,586.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 13/02/2012 00:44:16

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)